KR20090068385A - 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 - Google Patents
항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 Download PDFInfo
- Publication number
- KR20090068385A KR20090068385A KR1020097011311A KR20097011311A KR20090068385A KR 20090068385 A KR20090068385 A KR 20090068385A KR 1020097011311 A KR1020097011311 A KR 1020097011311A KR 20097011311 A KR20097011311 A KR 20097011311A KR 20090068385 A KR20090068385 A KR 20090068385A
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- receptor
- antibodies
- cells
- lupus erythematosus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (8)
- 항 인터루킨-6 (IL-6) 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및 치료제.
- 제 1항에 있어서, 상기 항 IL-6 수용체 항체가 항 인간 IL-6 수용체 항체인 것을 특징으로 하는 예방 및 치료제.
- 제 1항에 있어서, 상기 항 IL-6 수용체 항체가 항 IL-6 수용체 모노클로날 항체인 것을 특징으로 하는 예방 및 치료제.
- 제 1항에 있어서, 상기 항 IL-6 수용체 항체가 재조합형 항 IL-6 수용체 항체인 것을 특징으로 하는 예방 및 치료제.
- 제 1항에 있어서, 상기 항 IL-6 수용체 항체가 PM-1 항체인 것을 특징으로 하는 예방 및 치료제.
- 제 1항에 있어서, 상기 항 IL-6 수용체 항체가 인간 항체 정상 영역을 갖는 항체인 것을 특징으로 하는 예방 및 치료제.
- 제 1항에 있어서, 상기 항 IL-6 수용체 항체가 IL-6 수용체에 대한 키메라 항체 또는 인간화 항체인 것을 특징으로 하는 예방 및 치료제.
- 제 1항에 있어서, 상기 항 IL-6 수용체 항체는 인간화 PM-1 항체인 것을 특징으로 하는 예방 및 치료제.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22040097 | 1997-08-15 | ||
JPJP-P-1997-220400 | 1997-08-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087004911A Division KR20080027967A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107012126A Division KR20100068498A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20090068385A true KR20090068385A (ko) | 2009-06-26 |
Family
ID=16750530
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107012126A Ceased KR20100068498A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 |
KR1020087004911A Ceased KR20080027967A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제 |
KR1020097011311A Abandoned KR20090068385A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 |
KR1020007001448A Ceased KR20010022846A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 |
KR10-2003-7016315A Ceased KR20040024561A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107012126A Ceased KR20100068498A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 |
KR1020087004911A Ceased KR20080027967A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007001448A Ceased KR20010022846A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 |
KR10-2003-7016315A Ceased KR20040024561A (ko) | 1997-08-15 | 1998-08-14 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제 |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP1004315B1 (ko) |
JP (4) | JP2009185073A (ko) |
KR (5) | KR20100068498A (ko) |
AT (1) | ATE395933T1 (ko) |
AU (1) | AU747883B2 (ko) |
CA (1) | CA2296322A1 (ko) |
CY (1) | CY1108180T1 (ko) |
DE (1) | DE69839517D1 (ko) |
DK (1) | DK1004315T3 (ko) |
ES (1) | ES2308809T3 (ko) |
PT (1) | PT1004315E (ko) |
WO (1) | WO1999008707A1 (ko) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
AU2007232873B2 (en) | 2006-03-31 | 2014-02-20 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
DK2041177T3 (da) | 2006-06-02 | 2012-02-27 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
EP4339294A3 (en) | 2007-09-26 | 2024-10-16 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
CN102056946A (zh) | 2008-04-11 | 2011-05-11 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
TWI705072B (zh) | 2010-11-30 | 2020-09-21 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
CN103169966B (zh) * | 2013-04-09 | 2015-04-01 | 中国人民解放军军事医学科学院基础医学研究所 | 一种治疗系统性红斑狼疮的药物组合物 |
JP6442404B2 (ja) | 2013-06-11 | 2018-12-19 | 国立研究開発法人国立精神・神経医療研究センター | 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法 |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
WO2016186154A1 (ja) | 2015-05-19 | 2016-11-24 | 国立研究開発法人国立精神・神経医療研究センター | 多発性硬化症(ms)患者の新規治療適用判断方法 |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
JP7235249B2 (ja) | 2017-10-20 | 2023-03-08 | 学校法人兵庫医科大学 | 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
SG11202107735SA (en) | 2019-01-31 | 2021-08-30 | Sanofi Biotechnology | Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis |
WO2020247461A1 (en) | 2019-06-04 | 2020-12-10 | Sanofi Biotechnology | Compositions and methods for treating pain in subj ects with rheumatoid arthritis |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US521628A (en) | 1894-06-19 | Housekeeping-cabinet | ||
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
DE3835350A1 (de) | 1988-10-17 | 1990-04-19 | Boehringer Mannheim Gmbh | Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern |
JP2803199B2 (ja) * | 1989-08-07 | 1998-09-24 | 株式会社ニコン | カメラの警告装置 |
JPH03155795A (ja) | 1989-11-13 | 1991-07-03 | Chuzo Kishimoto | マウス・インターロイキン―6レセプター蛋白質 |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
EP0628639B1 (en) | 1991-04-25 | 1999-06-23 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
FR2694767B1 (fr) * | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
WO1995009873A1 (en) | 1993-10-06 | 1995-04-13 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
CN101361972B (zh) * | 1994-10-07 | 2011-05-25 | 中外制药株式会社 | 以il-6拮抗剂作为有效成分治疗慢性类风湿性关节炎 |
CN101829325A (zh) * | 1994-10-21 | 2010-09-15 | 岸本忠三 | Il-6受体的抗体在制备药物组合物中的用途 |
US6261560B1 (en) * | 1995-02-13 | 2001-07-17 | Chugai Seiyaku Kabushiki Kaisha | Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor |
AU5332196A (en) | 1995-03-31 | 1996-10-16 | Henrik Georg Bohr | Method for protein folding |
CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
JP3803199B2 (ja) * | 1997-08-15 | 2006-08-02 | 中外製薬株式会社 | 抗il−6レセプター抗体を有効成分として含有する全身性エリテマトーデスの予防および/または治療剤 |
JP2005247872A (ja) * | 1997-08-15 | 2005-09-15 | Chugai Pharmaceut Co Ltd | 抗il−6レセプター抗体を有効成分として含有する全身性エリテマトーデスの予防および/または治療剤 |
-
1998
- 1998-08-14 EP EP98937834A patent/EP1004315B1/en not_active Revoked
- 1998-08-14 DK DK98937834T patent/DK1004315T3/da active
- 1998-08-14 AT AT98937834T patent/ATE395933T1/de active
- 1998-08-14 WO PCT/JP1998/003636 patent/WO1999008707A1/ja active IP Right Grant
- 1998-08-14 EP EP08001023A patent/EP1916020A3/en not_active Ceased
- 1998-08-14 DE DE69839517T patent/DE69839517D1/de not_active Expired - Lifetime
- 1998-08-14 PT PT98937834T patent/PT1004315E/pt unknown
- 1998-08-14 KR KR1020107012126A patent/KR20100068498A/ko not_active Ceased
- 1998-08-14 KR KR1020087004911A patent/KR20080027967A/ko not_active Ceased
- 1998-08-14 AU AU86494/98A patent/AU747883B2/en not_active Ceased
- 1998-08-14 CA CA002296322A patent/CA2296322A1/en not_active Abandoned
- 1998-08-14 KR KR1020097011311A patent/KR20090068385A/ko not_active Abandoned
- 1998-08-14 ES ES98937834T patent/ES2308809T3/es not_active Expired - Lifetime
- 1998-08-14 KR KR1020007001448A patent/KR20010022846A/ko not_active Ceased
- 1998-08-14 KR KR10-2003-7016315A patent/KR20040024561A/ko not_active Ceased
-
2008
- 2008-07-08 CY CY20081100714T patent/CY1108180T1/el unknown
-
2009
- 2009-05-25 JP JP2009125791A patent/JP2009185073A/ja not_active Withdrawn
-
2012
- 2012-08-10 JP JP2012178718A patent/JP2012214517A/ja not_active Withdrawn
-
2015
- 2015-02-25 JP JP2015035784A patent/JP2015098491A/ja not_active Withdrawn
-
2016
- 2016-10-07 JP JP2016199315A patent/JP2017002087A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20040024561A (ko) | 2004-03-20 |
JP2009185073A (ja) | 2009-08-20 |
JP2015098491A (ja) | 2015-05-28 |
DK1004315T3 (da) | 2008-07-21 |
CA2296322A1 (en) | 1999-02-25 |
KR20080027967A (ko) | 2008-03-28 |
KR20100068498A (ko) | 2010-06-23 |
CY1108180T1 (el) | 2014-02-12 |
PT1004315E (pt) | 2008-07-09 |
KR20010022846A (ko) | 2001-03-26 |
AU747883B2 (en) | 2002-05-30 |
JP2017002087A (ja) | 2017-01-05 |
WO1999008707A1 (fr) | 1999-02-25 |
JP2012214517A (ja) | 2012-11-08 |
EP1004315B1 (en) | 2008-05-21 |
EP1916020A2 (en) | 2008-04-30 |
DE69839517D1 (de) | 2008-07-03 |
EP1004315A4 (en) | 2001-12-05 |
AU8649498A (en) | 1999-03-08 |
ES2308809T3 (es) | 2008-12-01 |
EP1004315A1 (en) | 2000-05-31 |
ATE395933T1 (de) | 2008-06-15 |
EP1916020A3 (en) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190002572A1 (en) | Preventive and/or therapeutic method for systemic lupus erythematosus comprising anti-il-6 receptor antibody administration | |
KR100838862B1 (ko) | 아이엘-6 안타고니스트를 유효성분으로 함유하는 감작 티 세포 관여 질환의 예방 또는 치료제 | |
US7771723B2 (en) | Remedies for myeloma to be used together with nitrogen mustard antitumor agents | |
JP2017002087A (ja) | 抗il−6レセプター抗体を有効成分として含有する全身性エリテマトーデスの予防および/または治療剤 | |
CA2341239C (en) | A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient | |
JP4776145B2 (ja) | Il−6アンタゴニストを有効成分として含有する乾癬の予防又は治療剤 | |
US8173126B2 (en) | Blood VEGF level-lowering agent containing IL-6 antagonist as the active ingredient | |
US20060292147A1 (en) | Blood MMP-3 level-lowering agent comprising IL-6 antagonist as active ingredient | |
CN101239185A (zh) | 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂 | |
JP3803199B2 (ja) | 抗il−6レセプター抗体を有効成分として含有する全身性エリテマトーデスの予防および/または治療剤 | |
JP2005247872A (ja) | 抗il−6レセプター抗体を有効成分として含有する全身性エリテマトーデスの予防および/または治療剤 | |
HK1096588B (en) | Therapeutic agent for mesothelioma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20090601 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20090803 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20100302 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20090803 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
A107 | Divisional application of patent | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20100601 |
|
PJ0201 | Trial against decision of rejection |
Patent event date: 20100601 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20100302 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20100723 Appeal identifier: 2010101004061 Request date: 20100601 |
|
PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20100601 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20100601 Patent event code: PB09011R01I |
|
PC1902 | Submission of document of abandonment before decision of registration | ||
SUBM | Surrender of laid-open application requested | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20100601 Effective date: 20100723 |
|
PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20100723 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20100601 Decision date: 20100723 Appeal identifier: 2010101004061 |